Captor Therapeutics S.A. Logo

Captor Therapeutics S.A.

ISIN: PLCPTRT00014 | Ticker: CTX | LEI: 259400JHH1S2I2S4O735

About Captor Therapeutics S.A.

Company Description

Captor Therapeutics is a biopharmaceutical company focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.

Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called "undruggable proteome".

Captor Therapeutics is a Swiss-Polish company. Captor GmbH entity operates in Basel, the pharma hub of Switzerland, providing excellent opportunities for business development, while our state-of-the-art laboratories are located in Wroclaw, Poland. Our integrated competencies and expertise in biology and chemistry allow us to perform all stages of early drug development.

Year founded


Served area



Duńska 11, 54-427 Wrocław – Poland

Filings & Publications

Shareholder information

Shares outstanding



April 1, 2021

Stock exchange(s)

Warsaw Stock Exchange



Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.